Depakote is a medication used to treat a variety of conditions, including epilepsy, bipolar disorder, and migraine headaches. It is a brand name for the drug divalproex sodium, and it is available in both immediate-release and extended-release forms. The drug was first approved by the FDA in 1983 and has been used to treat a variety of conditions since then.
History
Ingredients
Disadvantages
History
The drug was first approved by the FDA in 1983 and has been used to treat a variety of conditions since then. Before this, the drug was used in Europe for treating epilepsy, but it was not approved for use in the United States until 1983. The drug was developed by Abbott Laboratories and is still manufactured by them today.
Ingredients
The active ingredient in Depakote is divalproex sodium. It is also known by other names, such as valproic acid and sodium valproate. The drug is a type of anticonvulsant, which means it works to reduce the frequency of seizures. It works by increasing the levels of a neurotransmitter in the brain called gamma-aminobutyric acid (GABA). This neurotransmitter helps to regulate nerve activity in the brain.
Disadvantages
Despite its many benefits, there are some potential side effects of Depakote that should be taken into consideration before taking the medication. These side effects include nausea, vomiting, stomach pain, diarrhea, constipation, loss of appetite, weight gain, hair loss, and tremor. Additionally, long-term use of the drug can lead to liver damage, so it is important to monitor liver function closely when taking the medication. Other potential side effects include drowsiness, dizziness, and difficulty concentrating.
Depakote is an effective medication for treating a variety of conditions, but it is important to consider the potential side effects before taking it. It is also important to monitor for any changes in liver function when taking the medication, as long-term use can lead to liver damage. Talk to your doctor if you have any questions or concerns about taking Depakote.